PVI
CYTK icon

Pura Vida Investments’s Cytokinetics CYTK Stock Holding History

Pura Vida Investments’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-24,600
Closed -$204K – 115
2018
Q2 		$204K Buy
+24,600
New +$205K 0.08% 91

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Pura Vida Investments's CYTK Position: Q4 2022 in Review

Pura Vida Investments sold out of Cytokinetics (CYTK) in Q4 2022, closing a stake of 15,000 shares — an estimated $645K sold.

Pura Vida Investments first reported a position in CYTK in Q3 2019 and held it in 2 quarters. The position peaked at $12.6M in Q3 2022. 277 funds tracked by Wall St. Rank hold CYTK as of Q4 2022.

  • Pura Vida Investments reported no remaining Cytokinetics position as of Q4 2022 after selling out during the quarter.
  • Pura Vida Investments sold 15,000 Cytokinetics shares in Q4 2022, an estimated $645K.
  • Pura Vida Investments first reported a position in Cytokinetics in Q3 2019 and held it in 2 quarters.
  • Pura Vida Investments's Cytokinetics position peaked at $12.6M in Q3 2022.
  • 277 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2022.

Based on Pura Vida Investments's 13F filing for Q4 2022, filed 14 Feb 2023.